Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
VCYT - Veracyte, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$45.25
DETAILS
HIGH:
$52.00
LOW:
$37.00
MEDIAN:
$46.00
CONSENSUS:
$45.25
UPSIDE:
0.49%
Stock News
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i.
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Ver.
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors
On May 13, 2026, Veracyte Inc (VCYT) shares fell 3.3%, bringing the current price to $38.26. The stock has experienced a 52-week range of $22.61 to $50.71, show
Why Veracyte Stock Is Skyrocketing Higher This Week
Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow by double-digit rates.
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.
Veracyte Announces First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte's CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approac.
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers.
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a short-term bullish trend.
AEGON ASSET MANAGEMENT UK Plc Has $20.60 Million Position in Veracyte, Inc. $VCYT
AEGON ASSET MANAGEMENT UK Plc lifted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 489,418 shares of the biotechnology company's stock after purchasing an additional
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be av.
Comparing Advanced Biomedical Technologies (OTCMKTS:ABMT) and Veracyte (NASDAQ:VCYT)
Veracyte (NASDAQ: VCYT - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Veracyte and Advanced Biomedical
Is Veracyte Stock the Right Pick for Your Portfolio Now?
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Price Targets
Veracyte price target raised to $52 from $48 at UBS
$52.00
(was $39.44)
UBS
Veracyte price target raised to $42 from $40 at Canaccord
$42.00
(was $32.97)
Kyle Mikson
·
Canaccord Genuity
Veracyte, Inc (VCYT) PT Lowered to $37 at Morgan Stanley
$37.00
(was $34.68)
Kallum Titchmarsh
·
Morgan Stanley
Veracyte price target raised to $50 from $45 at Guggenheim
$50.00
(was $42.95)
Subbu Nambi
·
Guggenheim
Veracyte assumed with an Underweight at Morgan Stanley
$48.00
(was $46.39)
Morgan Stanley
Veracyte price target raised to $48 from $42 at UBS
$48.00
(was $43.64)
Lu Li
·
UBS
Veracyte, Inc (VCYT) PT Raised to $43 at Canaccord Genuity
$43.00
(was $36.12)
Kyle Mikson
·
Canaccord Genuity
Veracyte initiated with a Hold at Canaccord
$40.00
(was $35.83)
Kyle Mikson
·
Canaccord Genuity
Veracyte price target lowered to $28 from $29 at Morgan Stanley
$28.00
(was $27.37)
Tejas Savant
·
Morgan Stanley
Veracyte, Inc (VCYT) PT Raised to $44 at Needham
$44.00
(was $35.85)
Mike Matson
·
Needham
Veracyte price target raised to $26 from $21 at Morgan Stanley
$26.00
(was $29.41)
Tejas Savant
·
Morgan Stanley
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $23
$23.00
(was $21.00)
Morgan Stanley
Needham Maintains Buy on Veracyte, Lowers Price Target to $26
$26.00
(was $21.46)
Needham